GH
Bearish signalScored 2026-10-25 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Guardant Health, Inc.
- Nom
- Guardant Health, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Diagnostics & Research
- Bourse
- NASDAQ
- Capitalisation
- $22.7B
- Employés
- 2,498
- PDG
- Helmy Eltoukhy
- Site web
- https://guardanthealth.com
- Marché
- BDSXBLLNBNRCSTLFLGTGRAL
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 7 801 titres (~1 359 485,88 $ US)
- Insiders
- Tariq MusaAzar Alex M IIKrognes Steve E.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$5,550,182
Avg sell (VWAP, 90d window) $170.70 vs last close $173.25 (+1.5%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$194,031 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-16
- Liquidity
- Liquid $310,956,628/day · 20d vol
- Last synced
-
2026-10-27 09:40:30
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-16 | Tariq Musa | Sell · S | 116 | $165.88 | $19,242 | Form 4 |
| 2026-10-14 | Azar Alex M II | Sell · S · 10b5-1 | 69 | $159.89 | $11,032 | Form 4 |
| 2026-09-16 | Azar Alex M II | Sell · S · 10b5-1 | 826 | $175.00 | $144,550 | Form 4 |
| 2026-09-16 | Krognes Steve E. | Sell · S | 971 | $177.48 | $172,330 | Form 4 |
| 2026-09-16 | Tariq Musa | Sell · S · 10b5-1 | 116 | $175.00 | $20,300 | Form 4 |
| 2026-09-15 | Chudova Darya | Sell · S | 7,738 | $178.00 | $1,377,364 | Form 4 |
| 2026-09-11 | Kalia Kumud | Sell · S | 4,000 | $158.05 | $632,193 | Form 4 |
| 2026-08-17 | Tariq Musa | Sell · S · 10b5-1 | 116 | $156.45 | $18,148 | Form 4 |
| 2026-08-12 | Monroe Terilyn J. | Sell · S | 400 | $167.92 | $67,168 | Form 4 |
| 2026-08-10 | Freeman Chris | Sell · S | 17,413 | $170.24 | $2,964,401 | Form 4 |
| 2026-08-05 | Hidalgo Medina Manuel | Sell · S | 750 | $164.61 | $123,454 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-09-28 | Jonathan Jackson | Buy | $15,001 - $50,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-28 | Jonathan Jackson | Purchase | $15,001 - $50,000 |
| 2022-02-28 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2022-01-13 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2021-12-22 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-11-02 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-10-22 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-10-05 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-07-14 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-05-01 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-04-27 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-02-14 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-10-25 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
GH presents a moderate catalyst setup with an upcoming Q3 2026 earnings event and meaningful regulatory/clinical milestones (CE-mark approval, Shield adherence data), but the weak fundamental score (35) and chronic…
The first sentence of the analysis written for GH on 2026-10-25 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Unavailable or mixed. Current ratio 4.84 · operating margin -45% — readings disagree
Suggested stop 158.22, nearest stored support minus 0.5 ATR(8.7% under the last close). Reward/risk to the next stored resistance is 0.22. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 64.5% | 60.8% | 59.7% | 65.2% | 67.1% | |
| Ebit Margin | -42.1% | -58.5% | -84.4% | -144.8% | -102.2% | |
| Ebitda Margin | -38.1% | -52.8% | -76.8% | -136.8% | -96.2% | |
| Operating Profit Margin | -44.5% | -60.0% | -100.1% | -121.1% | -110.0% | |
| Pretax Profit Margin | -42.5% | -58.9% | -84.9% | -145.4% | -102.9% | |
| Continuous Operations Profit Margin | -42.4% | -59.0% | -85.0% | -145.6% | -103.0% | |
| Net Profit Margin | -42.4% | -59.0% | -85.0% | -145.6% | -108.6% | |
| Bottom Line Profit Margin | -42.4% | -59.0% | -85.0% | -145.6% | -108.6% | |
| Current Ratio | 4.843 | 4.677 | 6.542 | 6.167 | 5.723 | |
| Quick Ratio | 4.559 | 4.362 | 6.241 | 5.900 | 5.565 | |
| Solvency Ratio | -0.178 | -0.242 | -0.268 | -0.399 | -0.246 | |
| Cash Ratio | 1.249 | 2.330 | 5.505 | 0.733 | 2.528 | |
| Price To Earnings Ratio | -30.765 | -8.581 | -6.320 | -4.243 | -25.005 | |
| Price To Earnings Growth Ratio | 4.563 | 0.510 | 0.190 | -0.070 | -0.430 | |
| Forward Price To Earnings Growth Ratio | 4.563 | 0.510 | 0.190 | -0.070 | -0.430 | |
| Price To Earnings Diluted Ratio | -30.765 | -8.581 | -6.320 | -4.243 | -25.005 | |
| Price To Earnings Diluted Growth Ratio | 4.563 | 0.510 | 0.190 | -0.070 | -0.430 | |
| Price To Book Ratio | -128.951 | -26.852 | 19.090 | 46.182 | 15.711 | |
| Price To Sales Ratio | 13.040 | 5.074 | 5.372 | 6.182 | 27.120 | |
| Price To Free Cash Flow Ratio | -54.945 | -13.639 | -8.769 | -7.183 | -35.675 | |
| Price To Operating Cash Flow Ratio | -69.310 | -15.634 | -9.322 | -8.981 | -48.481 | |
| Debt To Assets Ratio | 0.849 | 0.899 | 0.758 | 0.850 | 0.623 | |
| Debt To Equity Ratio | -17.221 | -9.567 | 8.531 | 22.753 | 2.130 | |
| Debt To Capital Ratio | 1.062 | 1.117 | 0.895 | 0.958 | 0.680 | |
| Long Term Debt To Capital Ratio | 1.071 | 1.139 | 0.878 | 0.950 | 0.638 | |
| Financial Leverage Ratio | -20.277 | -10.638 | 11.258 | 26.753 | 3.418 | |
| Working Capital Turnover Ratio | 0.986 | 0.750 | 0.527 | 0.469 | 0.273 | |
| Operating Cash Flow Ratio | -0.610 | -1.063 | -1.578 | -1.602 | -1.074 | |
| Operating Cash Flow Sales Ratio | -0.188 | -0.325 | -0.576 | -0.688 | -0.559 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.261 | 1.146 | 1.063 | 1.250 | 1.359 | |
| Debt Service Coverage Ratio | -95.623 | -151.649 | -168.344 | -239.057 | -139.667 | |
| Interest Coverage Ratio | -112.201 | -171.869 | -219.055 | -211.245 | -159.488 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.108 | -0.180 | -0.240 | -0.226 | -0.152 | |
| Capital Expenditure Coverage Ratio | -3.825 | -6.836 | -15.863 | -3.995 | -2.786 | |
| Dividend Paid And Capex Coverage Ratio | -3.825 | -6.836 | -15.863 | -3.995 | -2.786 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -37.811 | -11.690 | -7.499 | -6.516 | -30.629 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 64.5% | ▲3.7% | ▲1.0% |
| Ebit Margin | -42.1% | ▲16.4% | ▲44.3% |
| Ebitda Margin | -38.1% | ▲14.7% | ▲42.1% |
| Operating Profit Margin | -44.5% | ▲15.5% | ▲42.6% |
| Pretax Profit Margin | -42.5% | ▲16.4% | ▲44.4% |
| Continuous Operations Profit Margin | -42.4% | ▲16.7% | ▲44.6% |
| Net Profit Margin | -42.4% | ▲16.7% | ▲45.7% |
| Bottom Line Profit Margin | -42.4% | ▲16.7% | ▲45.7% |
| Current Ratio | 4.843 | ▲0.166 | ▼-0.748 |
| Quick Ratio | 4.559 | ▲0.197 | ▼-0.766 |
| Solvency Ratio | -0.178 | ▲0.064 | ▲0.089 |
| Cash Ratio | 1.249 | ▼-1.080 | ▼-1.220 |
| Price To Earnings Ratio | -30.765 | ▼-22.184 | ▼-15.782 |
| Price To Earnings Growth Ratio | 4.564 | ▲4.053 | ▲3.611 |
| Forward Price To Earnings Growth Ratio | 4.564 | ▲4.053 | ▲3.611 |
| Price To Earnings Diluted Ratio | -30.765 | ▼-22.184 | ▼-15.782 |
| Price To Earnings Diluted Growth Ratio | 4.564 | ▲4.053 | ▲3.611 |
| Price To Book Ratio | -128.951 | ▼-102.098 | ▼-113.987 |
| Price To Sales Ratio | 13.040 | ▲7.966 | ▲1.683 |
| Price To Free Cash Flow Ratio | -54.944 | ▼-41.306 | ▼-30.903 |
| Price To Operating Cash Flow Ratio | -69.310 | ▼-53.676 | ▼-38.964 |
| Debt To Assets Ratio | 0.849 | ▼-0.050 | ▲0.053 |
| Debt To Equity Ratio | -17.221 | ▼-7.653 | ▼-18.546 |
| Debt To Capital Ratio | 1.062 | ▼-0.055 | ▲0.119 |
| Long Term Debt To Capital Ratio | 1.071 | ▼-0.069 | ▲0.136 |
| Financial Leverage Ratio | -20.277 | ▼-9.639 | ▼-22.380 |
| Working Capital Turnover Ratio | 0.986 | ▲0.235 | ▲0.385 |
| Operating Cash Flow Ratio | -0.610 | ▲0.453 | ▲0.575 |
| Operating Cash Flow Sales Ratio | -0.188 | ▲0.136 | ▲0.279 |
| Free Cash Flow Operating Cash Flow Ratio | 1.262 | ▲0.115 | ▲0.045 |
| Debt Service Coverage Ratio | -95.623 | ▲56.025 | ▲63.245 |
| Interest Coverage Ratio | -112.201 | ▲59.668 | ▲62.571 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -0.108 | ▲0.071 | ▲0.073 |
| Capital Expenditure Coverage Ratio | -3.825 | ▲3.012 | ▲2.836 |
| Dividend Paid And Capex Coverage Ratio | -3.825 | ▲3.012 | ▲2.836 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -37.811 | ▼-26.121 | ▼-18.982 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $12.81B | $3.75B | $3.03B | $2.78B | $10.13B | |
| Enterprise value | $14.14B | $4.56B | $3.25B | $4.01B | $11.01B | |
| EV / Sales | 14.40x | 6.17x | 5.76x | 8.91x | 29.48x | |
| EV / Op. cash flow | -76.52x | -19.01x | -10.00x | -12.95x | -52.70x | |
| EV / Free cash flow | -60.66x | -16.59x | -9.41x | -10.36x | -38.78x | |
| EV / EBITDA | -37.81x | -11.69x | -7.50x | -6.52x | -30.63x | |
| Net debt / EBITDA | -3.56x | -2.08x | -0.51x | -2.00x | -2.45x | |
| Current ratio | 4.84x | 4.68x | 6.54x | 6.17x | 5.72x | |
| Income quality | 0.44x | 0.55x | 0.68x | 0.47x | 0.54x | |
| Graham net-net | -$6 | -$5 | -$3 | -$4 | -$5 | |
| Tax burden | 99.7% | 100.3% | 100.1% | 100.2% | 105.5% | |
| Interest burden | 100.9% | 100.6% | 100.5% | 100.4% | 100.7% | |
| Working capital | $1.16B | $829.5M | $1.14B | $998.4M | $919.4M | |
| Invested capital | $1.57B | $1.12B | $1.46B | $1.36B | $1.25B | |
| Return on assets | -20.7% | -29.4% | -26.8% | -40.7% | -18.4% | |
| Operating ROA | -25.0% | -27.1% | -33.3% | -28.5% | -18.4% | |
| Return on tangible assets | -21.8% | -29.6% | -27.0% | -41.0% | -18.5% | |
| Return on equity | 419.2% | 312.5% | -302.1% | -1087.7% | -62.9% | |
| Return on invested capital | -25.1% | -34.4% | -35.1% | -37.8% | -20.3% | |
| Return on capital employed | -25.6% | -35.2% | -35.7% | -38.4% | -20.4% | |
| Earnings yield | -3.3% | -11.6% | -15.8% | -23.6% | -4.0% | |
| Free cash flow yield | -1.8% | -7.3% | -11.4% | -13.9% | -2.8% | |
| Capex / Op. cash flow | -26.1% | -14.6% | -6.3% | -25.0% | -35.9% | |
| Capex / Depreciation | 121.6% | 82.8% | 47.8% | 215.4% | 336.9% | |
| Capex / Sales | 4.9% | 4.7% | 3.6% | 17.2% | 20.1% | |
| SG&A / Sales | 71.9% | 73.8% | 80.0% | 103.2% | 106.7% | |
| R&D / Sales | 37.1% | 47.1% | 65.1% | 83.2% | 70.4% | |
| Stock comp / Sales | 16.9% | 19.0% | 16.1% | 21.1% | 40.5% | |
| Intangibles / Total assets | 5.1% | 0.7% | 0.7% | 0.9% | 0.8% | |
| Days sales outstanding | 51d | 54d | 57d | 79d | 95d | |
| Days payables outstanding | 57d | 49d | 83d | 161d | 114d | |
| Operating cycle | 141d | 144d | 157d | 199d | 186d | |
| Cash conversion cycle | 84d | 95d | 74d | 39d | 72d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-20 Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026 PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Mad.
- 2026-10-19 The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning Rate and energy headlines have kept the broad market jumpy, yet one sector keeps finding buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to record highs.
- 2026-10-15 These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
- 2026-10-15 Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing
- 2026-10-15 Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing the critical role of blood-based testing in increasing overall colorectal cancer (CRC) screening and follow-up colonoscopy adherence at the American College of Gastroenterology (ACG) 2026 Annual Meeting in Nashville, Tennessee. A modeling study looking at individuals 45 to 75 over a lifetime projected.
- 2026-10-15 Reviewing The Pennant Group (NASDAQ:PNTG) and Guardant Health (NASDAQ:GH) Guardant Health (NASDAQ: GH - Get Free Report) and The Pennant Group (NASDAQ: PNTG - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings. Earnings and Valuation This table compares Guardant
- 2026-10-08 Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca''s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360® CDx has received CE-marking under Europe''s in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from treatment with ETCAMAH™ (camizestrant), AstraZeneca''s next-generation oral selective estrogen.
- 2026-10-08 Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026 PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast wil.
- 2026-10-05 Guardant Health (GH) Price Forecast: Breakout Opens Path Toward $250 Guardant Health reaches record highs as bullish patterns align across timeframes, opening potential upside toward $250 if buyers defend key breakout support.
- 2026-10-05 Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published results from the COSMOS-MEL01 study (UMIN000042040). The study is the first published prospective, multicenter evaluation of the tissue-free, epigenomic Guardant Reveal™ blood test for molecular residual disease (MRD) detection and recurrence monitoring in patients wi.